Immunological function and prognostic value of lymphoid-specific helicase in liver hepatocellular carcinoma
Cancer Biomarkers · 2023
DOI: 10.3233/cbm-230073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biomarkers, 2023. Verfasst von Yuan Fang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Organ Transplantation Center, the First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, DNA Helicases, Biomarkers, Tumor. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Lymphoid-specific helicase (HELLS), a SNF2-like chromatin-remodeling enzyme, plays a key role in tumor progression via its DNA methylation function. However, the effects of HELLS on immune infiltration and prognosis in liver hepatocellular carcinoma (LIHC) remain uncertain. METHODS: The Tumor Immune Estimation Resource (TIMER) database was employed to explore the pan-cancer mRNA expression of HELLS and its correlation with immunity. GEPIA2 was used to verify the correlation between HELLS expression and survival. The role of HELLS in cancer was explored via gene set enrichment analysis (Gene Ontology and Kyoto Encyclopedia of Genes and Genomes) and the construction of gene-gene and protein-protein interaction networks (PPI). Additionally, correlations between DNA methylation, HELLS expression, and immune-related genes were explored in LIHC. HELLS expression in LIHC clinical samples was determined using qRT-PCR and western blotting. The effects of downregulated HELLS expression in hepatocellular carcinoma cells was explored via transfection experiments in vitro. RESULTS: High HELLS mRNA expression was identified in several cancers and was significantly associated with poorer prognosis in LIHC. Furthermore, HELLS expression was positively correlated with tumor-infiltrating lymphocytes and immune checkpoint genes in LIHC. Bioinformatics analysis suggested that DNA methylation of HELLS may be associated with the immune response. Results from the TCGA-LIHC dataset, clinical samples, and functional analysis indicated that HELLS contributed to tumor progression in LIHC. CONCLUSION: The study findings demonstrate that HELLS is an important factor in promoting LIHC malignancy and might serve as a potential biomarker for LIHC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Organ Transplantation Center, the First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
- Institute of Clinical Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
- Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Gastrointestinal and Hernia Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
- Otorhinolaryngology Head and Neck Surgery, Baoshan People's Hospital, Baoshang, Yunnan, China.
- Department of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Yunnan, China.
Zitieren
APA
Fang, Y., Tang, W., Zhao, D., Zhang, X., Li, N., Yang, Y., Jin, L., Li, Z., Wei, B., Miao, Y., Zeng, Z., & Huang, H. (2023). Immunological function and prognostic value of lymphoid-specific helicase in liver hepatocellular carcinoma. Cancer Biomarkers. https://doi.org/10.3233/cbm-230073
Vancouver
Fang Y, Tang W, Zhao D, Zhang X, Li N, Yang Y, et al. Immunological function and prognostic value of lymphoid-specific helicase in liver hepatocellular carcinoma. Cancer Biomarkers. 2023. doi:10.3233/cbm-230073
BibTeX
@article{Fang2023,
author = {Fang, Yuan and Tang, Weiqiang and Zhao, Dan and Zhang, Xiaoli and Li, Na and Yang, Yang and Jin, Li and Li, Zhitao and Wei, Benkai and Miao, Yinglei and Zeng, Zhong and Huang, Hanfei},
title = {Immunological function and prognostic value of lymphoid-specific helicase in liver hepatocellular carcinoma},
journal = {Cancer Biomarkers},
year = {2023},
doi = {10.3233/cbm-230073}
}
EUVIMED